Kennedy Ferruggia, Associate Editor

Semaglutide shows significant weight loss and reduces obesity-related health risks, offering a promising solution for effective weight management.

Inclisiran significantly enhances LDL-C goal attainment in patients post acute coronary syndrome, improving lipid management outcomes.

Consistent use of continuous glucose monitoring (CGM) significantly improves glycemic control in adults with type 2 diabetes (T2D).

Maternal type 1 diabetes may influence children's DNA, potentially reducing their risk of developing islet autoimmunity.

The FDA approves daratumumab and hyaluronidase for high-risk smoldering multiple myeloma, significantly improving patient outcomes and progression-free survival.

Leukogene's M2T-CD33 gains FDA orphan drug status, promising a novel immunotherapy approach for acute myeloid leukemia treatment.

Discover the importance of early screening for type 1 diabetes and how it can prevent life-threatening complications.

Oral semaglutide shows promise in enhancing glucose control and reducing cardiovascular risks.

Shara Bialo, MD, emphasizes the critical role of autoantibody screening in early T1D detection, enhancing patient outcomes during American Diabetes Month.

Multiplex respiratory virus testing enhances clinical decision-making for RSV in community hospitals.

Shara Bialo, MD, emphasizes the critical role of autoantibody screening in early T1D detection, enhancing patient outcomes during American Diabetes Month.

Continuous glucose monitoring (CGM) significantly enhances the detection of cystic fibrosis–related diabetes, outperforming traditional methods.

Low RSV vaccination rates among older adults in the US highlight missed opportunities for reducing hospitalizations and health care costs.

Environmental factors significantly influence the rising rates of type 2 diabetes in children.

Recent research reveals rising cancer rates among younger and older adults, linking obesity to increased incidence.

The FDA approves a simplified single-injection treatment for ulcerative colitis, enhancing patient experience with monthly dosing convenience.

The FDA updates sotatercept's label, enhancing treatment options for pulmonary arterial hypertension and reducing severe clinical events.

Language preference significantly impacts access to continuous glucose monitors for type 2 diabetes, revealing critical disparities in diabetes care.

FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma, enhancing treatment options and survival rates for patients with limited therapies.

Megan Dulohery Scrodin, MD, highlights Mayo Clinic's innovative COPD care model, emphasizing multidisciplinary collaboration and AI tools for improved patient outcomes.

Experts discuss breakthroughs in respiratory virus vaccines.

Research reveals varying impacts of GLP-1 receptor agonists on asthma risk, urging careful medication selection for patients with diabetes and respiratory issues.

A digital therapeutic app enhances access to behavioral cough suppression therapy.

James Chalmers, MBChB, PhD, discusses the ASPEN trial's findings on brensocatib's impact on lung structure and function in bronchiectasis patients.

Megan Dulohery Scrodin, MD, discusses COPD management challenges and the need for accessible care and cost reduction.

Sara Assaf, MD, shares insights on selecting biologic therapies for severe asthma, including biomarkers, patient factors, and managing nonresponders effectively.

The FDA's approval of GLP-1 for obstructive sleep apnea enhances treatment options, emphasizing pharmacists' vital role in patient care and management.

Pharmacists are uniquely positioned to help prevent nutritional deficiencies, manage adverse effects, and maintain long-term health through tailored guidance.

The FDA approves a groundbreaking 1-minute HIV self-test, enhancing accessibility and empowering individuals to manage their health discreetly.